Encompass Health Co. (NYSE:EHC) Shares Sold by Capital Research Global Investors

Capital Research Global Investors cut its holdings in shares of Encompass Health Co. (NYSE:EHC) by 0.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 780,929 shares of the company’s stock after selling 6,920 shares during the quarter. Capital Research Global Investors owned 0.78% of Encompass Health worth $72,119,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. increased its holdings in Encompass Health by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company’s stock worth $960,817,000 after purchasing an additional 138,196 shares during the period. Invesco Ltd. lifted its stake in Encompass Health by 3.3% in the fourth quarter. Invesco Ltd. now owns 5,536,251 shares of the company’s stock worth $511,273,000 after acquiring an additional 176,135 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of Encompass Health by 6.0% in the 4th quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company’s stock valued at $191,799,000 after purchasing an additional 117,617 shares during the last quarter. FMR LLC lifted its position in shares of Encompass Health by 0.8% during the 4th quarter. FMR LLC now owns 1,973,846 shares of the company’s stock worth $182,285,000 after purchasing an additional 15,831 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Encompass Health by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company’s stock worth $155,176,000 after purchasing an additional 6,164 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Insider Activity at Encompass Health

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.10% of the company’s stock.

Encompass Health Trading Down 6.9 %

NYSE EHC opened at $96.19 on Tuesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. Encompass Health Co. has a one year low of $79.26 and a one year high of $105.23. The firm’s fifty day moving average is $99.87 and its two-hundred day moving average is $98.30. The firm has a market cap of $9.69 billion, a PE ratio of 21.57, a P/E/G ratio of 2.31 and a beta of 0.87.

Encompass Health (NYSE:EHC) last announced its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Analysts expect that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st were paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date was Tuesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is 15.25%.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. KeyCorp upped their price target on Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Royal Bank of Canada reissued an “outperform” rating and set a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. StockNews.com cut shares of Encompass Health from a “buy” rating to a “hold” rating in a report on Wednesday, April 16th. Finally, Barclays lifted their price target on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.